Table 7.
Number and proportion of patients with early-stage breast cancer with adjuvant radiotherapy.
| Calendar year | Comparison to 2018/2019 | ||||
|---|---|---|---|---|---|
| 2018/2019 | 2020 | 2021 | OR (95% CI)a 2020 | OR (95% CI)a 2021 | |
| Overall | 7,335 (63.3%) | 3,351 (62.3%) | 3,491 (60.7%) | 0.94 (0.88–1.01) | 0.85 (0.79–0.91) |
| Grade | |||||
| Low (G1) | 1,231 (74.7%) | 565 (75.5%) | 522 (72.9%) | 1.00 (0.81–1.24) | 0.87 (0.71–1.08) |
| Intermediate (G2) | 4,332 (63.5%) | 1,999 (62.8%) | 2,124 (61.0%) | 0.97 (0.88–1.06) | 0.84 (0.77–0.92) |
| High (G3) | 1,540 (56.9%) | 638 (53.4%) | 647 (54.7%) | 0.83 (0.72–0.96) | 0.86 (0.74–1.00) |
| Type of surgery | |||||
| Breast-conserving | 7,048 (72.5%) | 3,213 (72.1%) | 3,351 (70.5%) | 0.96 (0.88–1.05) | 0.87 (0.80–0.94) |
| Mastectomy | 287 (15.4%) | 138 (15.0%) | 140 (14.0%) | 0.94 (0.74–1.19) | 0.84 (0.66–1.07) |
OR = odds ratio, CI = confidence interval; significant values are shown in bold; a odds ratios were extracted from a logistic regression model adjusted for age, grade, pre-surgical stage, hormone receptor status, HER2 status, and neoadjuvant treatment.